Origin Agritech Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SEED research report →
Price Chart
About the company
Established in 1997 and headquartered in Beijing, China, Origin Agritech Limited is a Chinese firm operating in two primary areas: agricultural biotechnology and an e-commerce platform. Its biotechnology segment focuses on the genetic enhancement and breeding of crop seeds, encompassing the development, production, and distribution of hybrid crop varieties and associated seed technologies. The firm also manages an e-commerce platform that caters to farmers across China, offering a diverse array of goods via online and mobile channels.
- CEO
- Weibin Yan
- IPO
- 2004
- Employees
- 97
- HQ
- Beijing, BE, CN
Get TickerSpark's AI analysis on SEED
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.65M
- P/E
- -0.66
- PEG
- -0.01
- P/S
- 1.32
- P/B
- -0.81
- EV/EBITDA
- -2.90
- Div Yield
- 0.00%
- Gross Margin
- 5.60%
- Op Margin
- -85.51%
- Net Margin
- -61.64%
- ROE
- 88.44%
- ROIC
- 109.47%
Latest fiscal year · YoY change
- Revenue
- $91.29M-19.5%
- Gross Profit
- $6.39M-60.2%
- Op Income
- $-53,805,000
- Net Income
- $-53,328,000-357.5%
- EPS
- $-7.03-319.7%
- OCF Growth
- -50.1%
- FCF Growth
- -79.6%
- 52W High
- $1.73
- 52W Low
- $0.60
- 50D MA
- $0.81
- 200D MA
- $1.03
- Beta
- 1.58
- RSI (14)
- 39
- Avg Volume
- 54.73K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Origin Agritech said first-half fiscal 2026 results showed lower revenue but improving operating leverage as it shifted toward new corn seed products and continued rebuilding its biotech and sales platform.· May 22, 2026
- Revenue fell 31.9% to RMB 49.2 million as the company reduced external seed tolling and prioritized new corn seed sales.
- Gross profit declined to RMB 5.5 million from RMB 8.1 million, while operating loss and net loss both improved materially year over year.
- Operating expenses dropped 43.9%, driven by a 69.8% cut in G&A, even as selling and marketing rose to support the 36-person sales force and Aoyun 2026 campaign.
- Management emphasized biotech commercialization, citing Hi3, Shunfeng gene-editing work, GMO readiness, and more than 200,000 germplasm resources.
- The company ended the period with RMB 13.4 million in cash, RMB 24.8 million in inventories, and RMB 9.5 million in short-term borrowings.
For the 6 months ended March 31, 2026, total revenues were RMB 49.2 million (USD 7.1 million), down from RMB 72.3 million, a decrease of approximately 31.9%. Gross profit was RMB 5.5 million (USD 0.8 million) versus RMB 8.1 million in the prior-year period. Operating expenses were RMB 18.4 million (USD 2.7 million), down 43.9% year over year; G&A fell 69.8% to RMB 7.6 million, selling and marketing rose 93.3% to RMB 5.1 million, and R&D increased 11.1% to RMB 5.7 million. Loss from operations improved to RMB 12.9 million (USD 1.9 million) from RMB 24.7 million, and net loss attributable to Origin Agritech improved to RMB 14.4 million (USD 2.1 million) from RMB 25.6 million; basic and diluted net loss per share was RMB 1.21 versus RMB 3.55. As of March 31, 2026, cash and cash equivalents were RMB 13.4 million, inventories were RMB 24.8 million, short-term borrowings were RMB 9.5 million, and total liabilities were RMB 168.1 million. Management did not provide quantified next-quarter or full-year revenue/EPS guidance, but said the second half of fiscal 2026 and first half of fiscal 2027 will be the key test of whether the rebuilt foundation is converting into commercial outcomes.
Weibin Yan framed the period as the midpoint of a multi-stage recovery plan, saying the company has moved from rebuilding capabilities to converting that foundation into measurable commercial and scientific outcomes. He highlighted over 30,000 new test-cross combinations, restoration of the sales team to 36 professionals, reentry into Northeast China, and the launch of the Aoyun 2026 program with KPI contracts across six regional sales companies. His tone was constructive and confident, repeatedly emphasizing that biotech is becoming a commercial story and that he believes the next reporting periods will show conversion.
Zheng Chen focused on the financial turnaround in expenses and losses. He pointed to the RMB 49.2 million revenue base, the RMB 5.5 million gross profit, and the steep drop in operating expenses to RMB 18.4 million, especially the reduction in G&A to RMB 7.6 million following the leadership restructuring and consolidation in Beijing. He also noted that selling and marketing increased to RMB 5.1 million to support the 36-person sales organization and Aoyun 2026, while R&D rose to RMB 5.7 million for Hi3, Shunfeng, and the new variety pipeline. On the balance sheet, he cited RMB 13.4 million in cash, RMB 24.8 million in inventories, RMB 9.5 million in short-term borrowings, and RMB 168.1 million in total liabilities.
Investors asked when China’s expanding GMO corn policy could turn into visible GMO revenue. Management said the policy direction is favorable but would not forecast Ministry of Agriculture timing; instead, it emphasized that Origin already has the BBL2-2 biosafety certificate, GMO crop seed production in Beijing Origin’s business scope, two crop seed production and operation licenses, and a licensing pathway through the Origin Marker Biological Breeding Service Consortium. Another question asked how Origin could compete for a top-three position by 2030 to 2032; management said the strategy is not conventional scale but a biotechnology stack built around Hi3, the Shunfeng patent license, AI-assisted breeding, GMO readiness, and related licenses. On AI-assisted breeding, management said it is being used for genomic selection, image-based phenotyping, and donor/recipient prediction for HI3 and Shunfeng editing, with the goal of reducing field seeds required per candidate and lowering R&D cost per validated trait.
The bullish case from this call is that Origin says the reset is now showing up in the numbers: G&A is sharply lower, operating losses are narrowing, and the company is investing selectively in sales and R&D rather than broad cost growth. Management also sounded increasingly confident that its biotech assets, GMO readiness, and AI-assisted breeding tools could become commercial advantages as China’s GMO policy window expands.
The main bear case is that revenue still fell 31.9%, reflecting a difficult transition away from external seed tolling and toward a new product mix that has not yet fully scaled. Cash remains modest at RMB 13.4 million, liabilities are still elevated at RMB 168.1 million, and management offered no specific next-quarter or full-year financial guidance, leaving the timing of commercialization and GMO monetization uncertain.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 70.1%
- Shares Outstanding
- 14.13M
- Float Shares
- 9.90M
of shares held by institutions
15 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Citadel Advisors LLC | 27.43K | ▲ 27.43K |
| Hrt Financial LP | 24.78K | ▲ 24.78K |
| First Wilshire Securities Management Inc | 19.50K | 0 |
| Cetera Investment Advisers | 15.35K | 0 |
| Oppenheimer & Co Inc | 13.00K | 0 |
| Xtx Topco Ltd | 10.93K | ▲ 10.93K |
| Ae Wealth Management LLC | 10.00K | 0 |
| Wells Fargo & Company/Mn | 5.00K | 0 |
| Ubs Group AG | 2.85K | ▲ 2.84K |
| Jpmorgan Chase & Co | 1.70K | ▲ 1.70K |
| Morgan Stanley | 948 | 0 |
| Osaic Holdings, Inc. | 250 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 23, 06 | FEINBERG JEFF | other | 0 |
| Jan 11, 06 | FEINBERG JEFF | buy | 150,000 |
| Jan 5, 06 | FEINBERG JEFF | buy | 7,219 |
| Jan 5, 06 | FEINBERG JEFF | buy | 15,500 |
| Dec 8, 05 | FEINBERG JEFF | other | 910,100 |
| Dec 8, 05 | FEINBERG JEFF | other | 910,100 |
| Jan 4, 06 | Urbach Steven | other | 22,000 |
| Jan 4, 06 | Urbach Steven | other | 22,000 |
| Dec 13, 05 | PROPPER RICHARD D | other | 147,200 |
| Dec 13, 05 | PROPPER RICHARD D | sell | 2,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SEED coverage
Recent articles, reports, and earnings notes.
No research on SEED yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SEED report →Origin Agritech Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement
globenewswire.com · Oct 30
Origin Agritech's Three New Corn Varieties Pass Preliminary National Review, Advancing Toward Commercialization
globenewswire.com · Oct 26
A Letter to Shareholders from Weibin Yan, Chief Executive Officer of Origin Agritech
globenewswire.com · Oct 21
Origin Agritech Announces Strategic Provincial Distribution Agreement for Corn Seeds in Shandong Province and Receives RMB 2.9 Million in Initial Payments
globenewswire.com · Oct 19
Origin Launches Stress-Tolerant Corn Breeding for Southwest China Markets, with Supports from Guizhou State Entities
globenewswire.com · Oct 15
Origin Agritech Receives Full US$2.8 Million from Previously Announced Private Placement at US$1.40 Per Share
globenewswire.com · Oct 13
Origin Agritech Strengthens Liquidity by Selling Its Xinjiang Seed Subsidiary and Leasing Back the Production Base
globenewswire.com · Oct 1
Origin Agritech Establishes R&D Center in Guizhou with Biotech Unit and State-Backed Seed Joint Venture
globenewswire.com · Aug 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.